Discovering drugs to treat coronavirus disease 2019 (COVID-19)

1. Update on the prevalence and control of novel coronavirus-induced pneumonia as of 24:00 on February 21. <i>http://www.nhc.gov.cn/xcs/yqtb/202002/543cc508978a48d2b9322bdc83daa6fd.shtml</i> (accessed February 23, 2020). (in Chinese).

2. Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia, The 6th ed. <i>http:// www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf </i>(accessed February 23, 2020). (in Chinese).

3. Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia, The 5th ed. <i>http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a/files/ab6bec7f93e64e7f998d802991203cd6.pdf</i> (accessed February 18, 2020). (in Chinese).

4. Stockman LJ, Bellamy R, Garner P. SARS: Systematic review of treatment effects. PLoS Med. 2006; 3:e343.

5. Su B, Wang Y, Zhou R, Jiang T, Zhang H, Li Z, Liu A, Shao Y, Hua W, Zhang T, Wu H, He S, Dai L, Sun L. Efficacy and tolerability of lopinavir/ritonavir- and efavirenz-based initial antiretroviral therapy in HIV-1-infected patients in a tertiary care hospital in Beijing, China. Front Pharmacol. 2019; 10:1472.

6. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, Kao RYT, Poon LLM, Wong CLP, Guan Y, Peiris JSM, Yuen KY. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax. 2004; 59:252-256.

7. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006; 6:67-69.

8. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) <i>in vitro</i>. Cell Res. 2020.

9. News: Abidol and darunavir can effectively inhibit coronavirus <i>http://www.sd.chinanews.com/2/2020/0205/70145.html</i> (accessed February 21, 2020). (in Chinese).

10. Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018; 153:85-94.

11. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci. 2017; 93:449-463.

12. News. <i>http://www.szdsyy.com/News/0a6c1e58-e3d0-4cd1-867a-d5524bc59cd6.html </i>(accessed February 22, 2020). (in Chinese).

13. Sheahan TP, Sims AC, Leist SR, <i>et al</i>. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020; 11:222.

14. Holshue ML, DeBolt C, Lindquist S, <i>et al</i>. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020.

15. Mild/Moderate 2019-nCoV Remdesivir RCT. <i>https://clinicaltrials.gov/ct2/show/NCT04252664 </i>(accessed February 22, 2020). (in Chinese).

16. Severe 2019-nCoV Remdesivir RCT. <i>https://clinicaltrials.gov/ct2/show/NCT04257656 </i>(accessed February 22, 2020). (in Chinese).

17. Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020. 2020.2001.2031.929042.

18. Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J Virol. 2016; 90:8924-8933.

19. Shanghai Institute of Materia Medica website, Chinese Academy of Sciences. A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University discover a group of old and traditional Chinese medicines that may be efficacious in treating the novel form of pneumonia. <i>http://www.simm.ac.cn/xwzx/kydt/202001/t20200125_5494417.html</i> (accessed February 22, 2020). (in Chinese).